.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Mallinckrodt
Queensland Health
QuintilesIMS
Argus Health
AstraZeneca
Covington
Teva
US Department of Justice
Medtronic

Generated: July 25, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Disodium cromoglycate formulations
Abstract:There is described disodium cromoglycate in a form having a bulk density of greater than 0.45 g per ml when measured according to British Standard Test No 1460 (1967). There are also described granular and unit dosage forms of disodium cromoglycate. The disodium cromoglycate is useful, e.g. in the treatment of certain conditions of the gastrointestinal tract.
Inventor(s): Taylor; James E. (Loughborough, GB2), Stevenson; Neil A. (Loughborough, GB2)
Assignee: Fisons Limited (Ipswich, GB2)
Application Number:06/067,104
Patent Claims: 1. Disodium cromoglycate produced by wet granulation in a form having a bulk density of from 0.34 to 0.7 g per ml. and containing less than 5% by weight of any other compound, with the exception of water.

2. Disodium cromoglycate according to claim 1 having a bulk density of from 0.53 to 0.66 g per ml.

3. Disodium cromoglycate according to claim 1 in hard granular form.

4. Disodium cromoglycate according to claim 1 containing none of any other compound, with the exception of water.

5. Disodium cromoglycate according to claim 1 in particulate form, wherein less than 20% by weight of the particles are greater than 200 microns in diameter.

6. Disodium cromoglycate according to claim 1 in particulate form, wherein not more than 60% by weight consists of particles of less than 60 microns diameter.

7. Disodium cromoglycate according to claim 1, wherein less than 20% by weight consists of particles of less than 60 microns diameter.

8. A unit dosage form containing 1 to 250 mg of disodium cromoglycate produced by wet granulation in a granular form having a bulk density of from 0.45 to 0.7 g per ml. and less than 5% by weight of any other compound, with the exception of water.

9. A unit dosage form according to claim 8 and containing no lubricant.

10. A unit dosage form according to any of claims 8 or 9 comprising a capsule which is from 60 to 80% full when loosely filled.

11. A unit dosage form of disodium cromoglycate produced by wet granulation containing more than 10% by weight of granular disodium cromoglycate having a bulk density of from 0.45 to 0.70 g per ml., from 5 to 12% by weight of water, and from 35 to 85% by weight of encapsulating material.

12. A unit dosage form according to claim 11 containing more than 50% by weight of granular disodium cromoglycate.

13. A method for alleviating the symptoms of a disorder of the gastrointestinal tract in which an allergic reaction is involved which comprises oral administration of an effective amount of disodium cromoglycate according to claim 1 to a patient suffering from such a condition.

14. A method for alleviating the symptoms of a disorder of the nose in which an allergic reaction is involved which comprises intranasal administration of an effective amount of disodium cromoglycate according to claim 1 to a patient suffering from such a condition.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Moodys
US Army
US Department of Justice
Teva
Boehringer Ingelheim
McKesson
Baxter
AstraZeneca
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot